S
Siolta Therapeutics
Early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases
About Siolta Therapeutics
Siolta Therapeutics is a clinical-stage biopharmaceutical company that develops live biotherapeutic products (LBPs) to prevent and treat diseases by modulating the human microbiome.
The company's platform integrates clinical data, bioinformatics, and microbial science to create precisely defined consortia of microbes. Siolta's primary focus is on the developing infant gut microbiome and its influence on immune system programming, a critical area for preventing allergic and inflammatory conditions.
By targeting the maternal-infant axis, Siolta aims to deliver therapeutic interventions that can establish a healthy microbiome from the earliest stages of life. The company's lead product, STMC-103, is a mixed-species LBP in clinical development for the prevention of atopic diseases such as eczema and asthma.
Siolta Therapeutics has secured substantial funding through Series B and C financing rounds, enabling the advancement of its clinical programs. The company also engages in strategic collaborations to further its research and development efforts.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Mar 2024 | $12M | $150M | Khosla Ventures · SymBiosis | ↗ |
| GRANT✓Other financing | Feb 2022 | — | — | US National Institute of Allergy and Infectious Diseases · National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Siolta Therapeutics is 1.8K monthly website visits, up 20% over the last three months. Siolta Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Siolta Therapeutics in the San Carlos ecosystem
The Siolta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Seventure Partners
Khosla Ventures
US National Institute of Allergy and Infectious Diseases
National Institutes of Health
Series A3 investors entered at this stage
Marc Benioff
Global Brain Corporation
SymBiosis
Other known investors4 additional known investors
University of California, San Francisco
California Life Sciences
Kirin Health Innovation Fund
MBC Biolabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Siolta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Siolta Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










